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Aims and objectives of the dissertation 
1. To provide a comprehensive literate review in the main scopes of fetal 
medicine including prevention; ethology of prenatal conditions and 
diseases; ultrasonography, biochemical and non-invasive prenatal 
screening and of course diagnostics. 
2. To summarize the clinically important and published findings in the field 
from the prevention up to the diagnostics.  
3. To find and collect the most sensitive screening methods and markers of 
the trisomies. 
4. To create and publish the population specific normograms of 
ultrasonography markers of the Hungarian population  
5. To find and describe the best ultrasonography screening methodology for 
autosomal trisomies. 
6. To develop more sensitive screening methods or techniques with the 
combination of new and old screening markers. 
7. To confirm or deny the first and only publication in our knowledge about 
combination of nuchal translucency and ductus venosus pulsatility index 
in the first trimester. 
8. To observer the possible efficacy of the second trimester facial markers in 
the first trimester screening. 
9. To observe the combination of the first and second trimester nasal bone 
length normogram. 
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1. Introduction 
1.1. Health 
Definition of health 
Health is a state of complete physical, mental and social well-being and not merely the 
absence of disease or infirmity.  
1.2. Prevention 
Definitions of the prevention: 
To define the prevention and find the correct word on it we need to check several definitions 
of prevention.   
(1) “Prenvention in nursing care: actions directed to preventing illness and promoting health 
to reduce the need for secondary or tertiary health care. Prevention includes such nursing 
actions as assessment, including disease risk; application of prescribed measures, such as 
immunization; health teaching; early diagnosis and treatment; and recognition of disability 
limitations and rehabilitation potential. In acute care nursing many interventions are 
simultaneously therapeutic and preventive”.(1) 
(2) “The management of those factors that could lead to disease so as to prevent the 
occurrence of the disease.” (2) 
(3) “The prevention in disease control terms includes measures designed to prevent the 
introduction of a disease into areas where it does not already exist, and improve the resistance 
of the population and reduce the chances of the infection spreading, when the disease already 
exists in the population.” (3) 
(4) “Action so as to avoid, forestall, or circumvent a happening, conclusion, or phenomenon 
(for example, disease prevention).(4) (5) mid-15c., "action of stopping an event or practice," 
from Middle French prévention and directly from Late Latin praeventionem (nominative 
praeventio) "action of anticipating," noun of action from past participle stem of praevenire 
(see prevent). (5) 
 
In contrast to the „promoting health” was found alone in a definite, and the words of „disease” 
and „factors” were used in a several times by other definitions.   
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Prevention in Fetal Medicine 
During literature review the definition of prevention in fetal medicine was not found. Thither 
are many reasons, why it is necessary and why not recommended to create the definition 
preventive fetal medicine. Nevertheless, to keep the ethical aspects he definition of prevention 
in fetal medicine must be legalized. 
To use definitions of prevention in the fetal medicine, we bear to adjust and mix their aspects.  
„The prevention in fetal medicine is actions directed to promoting their health before, during, 
and after the pregnancy, to decrease and assess risk of risk factors and to preventing the feto-
maternal diseases, abnormalities and adverse outcomes of pregnancy.” 
This complex definition is not fully satisfactory but could be useful to see the grandness of 
this thesis, and might be used by some other publication, besides. 
1.3. Medical Genetics 
Medical Genetics is a medical specialty made up of clinical geneticists who are physicians 
certified in multiple or different clinical specialties. 
The aim of the medical genetics is to find, to prevent, to observe and to cure factor or the 
background of the single gene, polygenetic, epigenetic and complex disease in humans. 
Before a genetic test, there is pre-test consultation where a genetic counselling with detailed 
information have been given to the subject(s) (and their relatives if necessary).  The result and 
another detailed counselling will be given after the post-test genetic counselling.  
1.4. Fetal Medicine 
Definition of fetal medicine 
A multidisciplinary branch of medicine that trades with the growth, development, prevent, 
care, and treatment of the fetus and with environmental components that may harm the fetus. 
The major area of fetal medicine is the major physical anomalies. Which could be observed 
cc. They are seen in approximately 3-6% of newborns. (6) The "major physical anomaly" 
means a physical anomaly that has cosmetic or functional significance, another 1-3% will 
have malformations (including internal, genetic - Biochemic, structural, mental, or perceptive 
condition) detected later in childhood or life. These congenital malformations account for 
about 20% of deaths in the perinatal period.  
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Scope of the fetal medicine  
Fetal medicine has many interrelated studies such as maternal medicine, obstetrics, public 
health, midwifery, gynecology, birth rate, medical genetics and genomics, epigenetics, 
Neonatology, Perinatology, pediatrics, radiology...etc.  
Aim of the fetal medicine 
The aim of the fetal medicine to observe, define, prevent, evaluate factors of fetal 
development and find solution or prevention strategy to fetal diseases.  
Many countries has been ’separated’ from another branch of medicine and using as a unique 
field with or without maternal medicine (fetal medicine or feto-maternal medicine). 
Thither was a substantial demographic change in the maternal age in the Hungarian 
population. A drastic decline can be observed in the proportion of women under 25, while a 
significant increasing tendency in the proportion of women over 30 or more. The rate of 35 
year old or older pregnant increased 15.6% till 2009 with more than 7% from 2001. (see 
Figure 1) 
 
Figure 1 Live births by age-group of mother per 1000 females of corresponding age between1970 and2009  
Source: Hungarian Congenital Abnormality Registry (HCAR) 2011 
Department of Hungarian Congenital Abnormality Registry (HCAR or VRONY) is a good 
monitor of fetal defects in Hungary. Approximately 5-6% of fetuses have congenital 
abnormalities at birth in Hungary (HCAR National Report of Birth Defects, 2011).  
 
The incidence of fetal anomalies has been increased during the last decades (Figure 2), 
however many studies suggesting that’s could be the issue of the modern lifestyle or the 
improved health and more developed technologies. 
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Figure 2 Birth defects (cases per thousand) between 1990 and 2009 in Hungary (Source: HCAR 2011) 
(Figure 2. Orange rhomboid in 2007 is without minor anomalies: hernias, haemangioma, etc. 
The blue line is online notifications.) 
Not only the increasing maternal age, but there are many teratogen agents which are 
threatening and effecting fetal conditions.  
Fortunately, there are many new promising results which could decrease the incidence of a 
numerous feto-maternal abnormalities. 
1.4.1. Teratogen agents 
In humans, congenital disorders resulted in nearly 510,000 deaths globally in 2010. 
Teratogenic agents cause approximately 7% of congenital malformations. The teratogens 
causes a higher risk of birth defects and developmental abnormalities. These factors could be 
biological (Rubeolla or Parvo B13 viruses), physical (such as high temperature or X-ray), or 
chemical (such as thalidomide, tetracyclines or high dosage of vitamin A). Teratogen 
registries have been sorted out into classes A, B, C, D, X where A and B show no evidence of 
risk and C, D, and X show evidence of danger. Many times the data arrives from retrospective 
and uncontrolled studies so information is usually not complete, although there are a few, 
which were well documented and proven. 
There is no absolute teratogen agent so the outcome of the teratogen agent should observe by 
fetal medicine specialists and consulted by a medical genetics.  
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The effect of teratogen is highly dependent from the gestational age and the dosage of 
teratogen.  
1.4.2. Prevention of feto-maternal diseases 
The prevention of the fetal could be happened with preventive agents and with medical 
procedures, too. The levels of prevention must be included in the pregnancy care protocol. 
Personalized pregnancy care and preventive direction should be offered to all pregnant. 
1.4.3. Preventive agents 
Many intrauterine and post-partum condition could be primarily prevented by different type 
of diets and chemical agents. 
Czeizel et al. have been published about primarily prevention effect of by pre- and 
periconceptional folate administration in neural tube defects, limb-reduction and cardiac 
defects (7-9), with this findings our upcoming study preliminary results suggesting that more 
than 70% of neural tube defects and 30% of cardiac defects could be successfully prevented.  
Figure 3 Sensitivity of of teratogens during pregnancy (Columbia University, USA, Thomson Higher 
Education, 2007) 
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However, Corby reported aspirin as contraindicated agent during pregnancy in 1978. (7) One 
and two decades later Wallenberg et al. (8) and Beroyz el al. (12) have been published the 
good outcome of low-dose aspirin in the prevention of preeclampsia (PE)  in a randomized 
trial on more than 9000 patients.mized trial on more than 9000 patient. Various tasks have 
been set up to follow the beneficial effect of platelet aggregation inhibitors during pregnancy, 
these subject areas highlighted the effect of Low-dose aspirin started at 16 weeks or earlier 
was associated with a substantial reduction in preeclampsia, preterm delivery and intrauterine 
growth restriction (IUGR). (9) 
This effect could be extended with decreased level of protein intake and increase level of 
greens intake. Now aspirin is a commonly used agent to prevent preeclampsia. Before 
pregnancy, aspirin should be extended to adult females, who affected by anti-phospholipid 
syndromes (APLS). 
Preliminary studied were suggested that the optimal dose of magnesium agents (such as 
magnesium lactate or magnesium sulforicum) in combination with vitamin B6 (pyridoxine) 
could lessen the danger of preterm delivery (tocolytic), fetal cardiac defects, ADHD in the 
childhood, maternal anxiety and tension. (10-14) In combination magnesium with Vitamin B6 
and B12 have a good effect on the maternal gastrointestinal system and heart. It could also 
decrease the rate of negative pregnancy symptoms (such as nausea) and miscarriage. (15) 
The Vitamin D prophylaxis as a prevention could decrease the deficiency of vitamin D has 
been linked with a greater hazard of pregnancy complications, such as preeclampsia; decrease 
the incidence of  wheezing, asthma, rhinitis and allergic in childhood; decrease the risk of 
maternal gestational diabetes and a lower likelihood of a mother needing a Caesarian section. 
Still, the D vitamin is acting as an important agent in healthy and normal bone and immune 
development in utero. FDA recommendations for the daily intake is 200UI but for a pregnant 
or lactating woman it should be increased up to the daily limit (4.000-6.000UI/day for 
pregnant and 4.5-6.500UI/day for lactating women,) because the toxic dose of vitamin D is 
over 40.000UI/day (during the summer up to 20.000UI/day could be put out by the sun). 
Another positive side effect of vitamin D intake is the preconception effect because vitamin D 
is decreased the risk autoimmune abortion and increase the pace of fecundity in the overall 
population. (16-22) 
Women with PCOS at least 1000UI/day intake of vitamin D had two times higher fertility rate 
compared to a woman with average intake (2,2UI/day in Hungary), but the clinical detail of 
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sentiment for the readiness of the pregnancy could be the same level as inter-pregnancy 
recommendations (4.000UI/day independently from the seasons). (17,18,21,23,24) 
Antioxidant such as vitamin C and E could decrease the adverse pregnancy outcome (such as 
preterm delivery) and positive adulthood outcome (decreased incidence of age-related 
macular degeneration, amyotrophic lateral sclerosis, clogged arteries, scar, atopic eczema or 
dermatitis, heart diseases, cataract, cancer (colon, breast), dementia (Alzheimer’s), 
Parkinson’s and liver diseases). Some new randomized or cohort studies have been published 
on these findings till now so this will not remain level D evidence, anymore. (25-29) 
Vitamin E is also act as important factor in male reproduction, sufficient level of vitamin D 
could increase fertility. (17,18,21,23,24) 
The evolution of central nervous system is very complex. Some preliminary studies proved 
the beneficial effects of Omage-3 acids, DHA and EHA. These factors could decrease the risk 
of abnormal development of central nervous system (such as schizophrenia or autism) and 
also could increase the level of predicted intelligence up to 20%. (21,30). 
1.4.4. Methods in fetal medicine and medical genetics 
1.4.5. Family planning 
Family planning allows people and couples to anticipate and make their desired number of 
tykes and the spacing and timing of their births. It is achieved through the use of contraceptive 
methods and the treatment of involuntary infertility. A woman’s ability to space and limit her 
pregnancies has a direct impact on her wellness and wellbeing as well as to the gist of each 
pregnancy. (WHO, 2010) 
 
Positive family planning helps parents to hold a (healthy)  baby, it is a lot more important if 
the parents have a familial disease. 
1.4.6. Genetic counselling services  
Genetic counselling should be necessary if family history and/or screening test are positive 
and/or maternal anxiety is higher. Each counselling should personalized to the patient(s). 
1.4.7. The current status of preimplantation genetic diagnosis. 
Pre-implantation genetic diagnosis (PGD) is mostly defined as the in vitro genetic 
(cytogenetic or molecular) testing the embryo before embryo transfer and its implantation.  
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1.4.8. Fetopatology and post-mortem radiology 
Fetopatology and post-mortem radiology (such as CT or X-ray) is necessary to observe the cause of 
the fetal death. 
1.4.9. Risk estimation and assessment 
To evaluate the efficacy of a particular screening method and to evaluate the risk of a fetal 
condition, a risk estimation is necessary. Family tree should be created by the monogenic and 
by some polygenic disease to observe and explain the real risk. All screening tests had to have 
calculated sensitivity (detection rate), specificity (true negative rate), positive and negative 
predictive values,  likely-hood ratios and cut off values (this could be chosen). 
Detection rate or true positive rate: provides the proportion of actual positives which are 
correctly identified as true positives by the screening test. True negative rate: provides the 
proportion of negatives which are correctly identified as true negatives by the screening trial. 
Positive predictive value (PPV): proportion of positive results that are true positives.  
Negative predictive value (NPV): proportion of negative results that are true negatives.  
The false negative rate is one minus the detection rate and false positive rate one minus 
specificity, the booth should be as low as possible or acceptable compared to the risk of 
diagnostic procedures.  
Likely-hood ratios give a good chance to the practitioner to estimate the risk of the 
multifactorial hazard. The positive likely-hood ratio could increase the risk of a condition by 
its multiple if the marker was positive and/or higher than cut-off. Negative likely-hood ratio 
could decrease the risk of a fetal condition if the marker was negative or lower than the cut-
off. The sum total of multiple markers’ likely-hood ratio is depending on their linkage or 
correlation. The clinical introduction of these ratios is easy: Example: Background risk of a 
disease 1:1 =1, Marker one: Positive and its positive likely-hood ratio is 6x (increase the risk 
six times) Marker two: Negative and its negative likely-hood ratio is 0.5x (decrease the risk to 
half) 
𝐿𝑅 (𝑜𝑣𝑒𝑟𝑎𝑙𝑙) = 𝐵𝑅 𝑥 𝐿𝑅(𝑚𝑎𝑟𝑘𝑒𝑟1) 𝑥 𝐿𝑅(𝑚𝑎𝑟𝑘𝑒𝑟2) 
3 = 1 × 6 × 0.5 
The result is three times higher than the overall risk of the condition or compared population’s 
background risk, the likelihood ratio of the disease could be much easier explained than other 
methods. 
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The higher risk of a condition does not mean that the condition is exiting because there are no 
absolute screening marker. Diagnostic test or analysis of other screening factor is even 
necessary. 
Cut-off value is a term at what level and limit of risk is considered to be screen positive. Cut-
off values could be based-on manual or personal selection, or study proven results (for 
example FPR 5% limit) or in the most case 90th-95th-or-97th-or-99th percentile were used in 
the literature. To this study 97th and 99th percentiles were used. 
Invasive diagnostics should be offered if the cut-off risk reaching the cut-off limit or multiple 
marker of a condition is over cut-off value.  
1.4.10. Prenatal screening 
Prenatal screening for fetal malformations means to detect embryos or fetuses with normal or 
abnormal features during their intrauterine life. 
1.4.11. Ultrasound screening 
The ultrasound screening is the one of the oldest way to follow-up the pregnancy. In the last 
few decades, the technical development and science were reached the new era prenatal 
screening. These innovations help us to observe the fetus on high-definition live images or 
volumes. Ultrasound screening is able to detect developmental, chromosomal and structural 
abnormalities. 
The ultrasound screening needs normal ranges, these called reference ranges, normograms, or 
normograms in the literature. These reference intervals are necessary to calculate the real 
gestational age and follow the fetal development.  
To create normal ranges an advanced statistical knowledge is necessary. The complexity and 
requirements of the normogram creation was published by our group in Hungarian Medical 
Journal (Orvosi Hetilap).(31) Another publication of our research group proved usefulness of 
combined normograms was published.  
1.4.12. Biochemical screening or maternal serum screening 
Biochemical screening is introduced with AFP and HCG measurement in the middle of 80es, 
its overall screening performance was not higher than 40% sensitivity at 20-40% false 
positive rate. In the last decade multiple markers (such as PAPP-A, eostradiol, PlGF) were 
presented in the fetal medicine. 
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1.4.13. Combined Screening 
The combination of the ultrasound and biochemical markers has improved the efficacy of the 
screening. The ultrasound dating by using CRL is successfully solved the vulnerabilities of 
the biochemical screening. The correct dating is allowed to use them as MoMs values 
(Multiple of Medians) which are age, habitual and gestational age specific values. These 
values are really useful in biochemical screening but not as much as during the ultrasound 
screening. 
1.4.14. Non-invasive prenatal testing 
Non-invasive prenatal testing (NIPT) is based-on fetal cell free DNA in maternal plasma. This 
method is could be easily used in the clinical practice, but actually basically big companies 
earn a huge profit. Olive Kagan and  et al. has been published (in press in UOG) a QUALY 
based study comparing the new and old methods for screening for trisomies, this publication 
was suggested that NIPT is more expensive and not wide specturumed as combined or 
ultrasound screening. 
This method is brand new. Till this time, there is no restrictions, no ethical observation or no 
further control of the samples is exits. This will be a very big and serious deal, because two 
(mother and fetus) plus a half (father) patients genetic data could be observed without a 
warning or acceptance. Private life and health insurance companies could use these data in 
future to find risk gene of complex disease (such as cancer, cardiovascular diseases...etc). The 
parents and fetus does not known about this risk. 
Another possible field of usage is the Y detection to determine the sex of the fetus, which 
could be easily lead to demographic problems such as it happened before in the Far East 
regions (like China) during the introduction of CVS in 1980s. 
1.4.15. Prenatal diagnostics 
Prenatal diagnostics means to detect genetic diseases in the fetus using invasive procedures 
and genetic techniques. 
1.4.16. Invasive procedure 
The aim of the invasive procedure is to get a sample from a fetal cell culture for a genetic test. 
Because of the needle puncture for sampling the invasive prenatal method is the other term 
used. Ultrasound controlled sampling could be performed in the first trimester (Chorionic 
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Villus Sampling - CVS), or in the second trimester (Amniocentesis - AC) or later in the 
pregnancy (cordocentersis  - CC). The major problem of the sampling procedures is the risk 
of abortion, while the advantage is the certainty of the result which is above 99.8 per cent.  
Reviewing the literature, from end of 80s up today, a huge decrease of the invasive procedure 
associated risk could be observed. Commonly known, AC and CVS risk were about 1-2%, 
however the education, trainings, and experience proves that there is no significant difference 
if the procedure technique was appropriate and the protocols were followed. The latest 
publication in this field suggesting that the procedure of miscarriage  
The decision has been made by the parents, which based-on the estimated risk of aneuploidies 
in contrast to the risk of miscarriage associated with invasive procedures.  
Recent Guideline of the Hungarian College of Clinical Geneticist and of Obstetrics and 
Gynaecology (2010) recommends that all pregnant women of 37 years of age or over should 
be offered invasive testing to obtain a definitive diagnosis of fetal karyotype. However, from 
an ethical point of view the couples are left to have an autonomous decision if they want to 
have an invasive test or not. At genetic counselling the patient is advised to the possibility that 
they can skip the expensive screening and can go straight for invasive testing. 
A huge series of studies were presented on the risk of post procedure miscarriage. The 
significant discordance between the number should be observed and should be implicated to 
the genetic counselling. (32-37) 
Table 1 Risk of misscarige with and without invasive procedures (literature review) 
Invasive Procedure Risk of PPM or SM Optimal GA Sens. / Rep 
Chorionic Villus Sampling 0.17-2.7% 10-12wks 98% / 2.3% 
Spontaneous miscarriage  cc. 1% 10-12wks N/A 
Amniocentesis 0.06-2.3% 14-20wks 99% / 1.3% 
Spontaneous miscarriage  less than 0.5% 14-20wks N/A 
Cordocentersis   0.3-3% From 18-20wks 98% / 2.6% 
Spontaneous miscarriage  less than 0.1% From 18-20wks N/A 
PPM: Post Procedure Misscarriage; SM: Spontaneous miscarriage.Optimal GA: 
Optimal gestational age of procedure, Sens.: Sensitivity (incl. polluted sample or 
unsuccessful procedures); Rep.: Repetition of procedure is necessary. wks: weeks 
 
However, the invasive techniques have been become a routine and the likelihood of fetal loss 
is decreased to cc. 1.1 in the last decades. During the pre-test genetic counselling their 
complications and risk of iatrogenic fetal abnormalities should be present to the patients. 
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2. Fetal loss and aneuploidies 
More than 75% of the pregnancies has been ended with spontaneous abortion until the 6 
weeks. Most of these abortions are affected with some kind of numeric abnormalities (see 
Table 1.). The demographic trends have shown the increasing maternal age at the first and 
second pregnancy, which increase the risk of genetic abnormalities. 
The trisomy is the major factor in the background of the early fetal loss. (See Table 3.) The 
prevalence of all types of chromosomal abnormalities at birth is 1.88% (including asymptotic 
and balanced cases. 
2.1. Human karyotype 
The diploid (2N euploid) human karyotype contains 46 chromosomes.  Two sex and forty-four 
autosomal chromosome are each of them paired.  
Human karyotype could be investigated cytogenetically from different types of samples (such as 
blood, or other tissue). For fetal karyotyping an invasive procedure is required.  
2.2. Aneuploidies 
Aneuploidy is the one of the major categories of chromosome mutations in which 
chromosome number is abnormal. An aneuploid is an individual whose chromosome number 
differs from the 46 by part of a chromosome set. Generally, the aneuploid chromosome set 
differs from 46 by only one or a small number of chromosomes. Aneuploids can have a 
chromosome number either greater or smaller than that 46. Aneuploid nomenclature is based 
on the number of copies of the specific chromosome in the aneuploid state. For example, the 
aneuploid condition 2n −1 is called monosomic (meaning “one chromosome”) because only 
one copy of some specific chromosome is present instead of the usual two found in its diploid 
progenitor. The aneuploid 2n+1 is called trisomic, 2n−2 is nullisomic, and n+1 is disomic. 
The frequency of all chromosomal abnormalities has been analyzed in Table 3, using data of  
United States Environmental Protection Agency (Texas). A significant difference was 
observed between under pregnancy (Sp. AB and fetal death) and newborn samples. 
The features, symptoms, outcome and prognosis of the most common aneuploidies (Down 
Syndrome, Edwards syndrome, Patau syndrome, Tuner syndrome, trisomy 16  and polyploids 
have been summarized in Table 2. 
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2.2.1. The Down syndrome 
In 1886, Dr. John Langdon Down was described firstly Down syndrome as the part of the 
“Observations on an Ethnic Classification of Idiots” (38). Nowadays, the Down syndrome is 
the most frequent numerical chromosomal abnormality. Down syndrome is also known as 
trisomy 21, but the old terminology, mongoloid idiotism must not be used in the clinical 
practice. 
The trisomy of 21 chromosomes causes several but a wide range of developmental errors, 
physical and mental handicaps, most of them could be observed already in the fetal life. No 
effective cure of Down syndrome has been developed until now. Fetus affect with Down 
syndrome showed promising results with fetal programing, but this is only some approaches 
to decrease the symptoms. Nowadays, the prevention by early diagnosis and therapeutic 
abortion could be the possible choice.  
The prevalence of registered Down syndrome cases has been increased since the middle of the 
80es’. The birth prevalence of Down syndrome has not increased significantly, which means 
the efficacy of screening for trisomies is not optimal or the rate of Down syndrome affected 
fetus is increased. (See Figure 5) Prevalence of Down syndrome between 2001 and 2009 was 
1,78 ‰ (1:563 total births) in Hungary.  
 
Figure 4 The prevalence of Down Syndrome (cases/thousand) between 1970 and 2009. 
The correlation between the new screening method of Down syndrome and registered prevalence of 
Down syndrome could be observed from the middle of 80es. However, the rate of case should not be 
changed. 
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2.2.2. Edwards syndrome 
Trisomy 18 was independently described by Edwards (31) et al and Smith (32) et al in 1960. 
Among liveborn children, trisomy 18 is the second most common autosomal trisomy after 
trisomy 21. Trisomy 18 is characterized by severe psychomotor and growth retardation, 
microcephaly, microphthalmia, malformed ears, micrognathia or retrognathia, microstomia, 
distinctively clenched fingers, and other congenital malformations. 
2.2.3. Patau syndrome 
Trisomy 13 or Patau syndrome is a trisomy disorder. It is caused by the presence of a whole 
extra copy (or occasionally partial extra copy) of chromosome 13. Patau syndrome, in 75%-
90% of cases, is the result of the presence of a whole extra (third) copy of chromosome 13, 
hence its alternative name of trisomy 13 (or simple trisomy 13). Patau syndrome is caused by 
a chromosomal translocation in 5%-10% of cases, and to mosaicism (whereby only some cells 
have the extra copy of chromosome 13) in 5%. In occasional cases, it is only a part of 
chromosome 13 that is extra (partial trisomy 13). Occurrence in live births is about 1 in 9,500 
(in the absence of any prenatal detection program), and rises with increasing maternal age. 
Trisomy 13 is associated with a high rate of spontaneous loss of pregnancy (64% loss rate 
from the 2nd trimester onwards) and very poor chances of survival in neonates (median 
survival is 10 days). 
2.2.4. Aneuploidy of the Sex Chromosomes 
However, sex chromosomes are rarely affected by aneuploidies, their screening and diagnosis 
is still not solved. There are numerous syndrome known with additional X or Y chromosomes 
(ei. XXX, XXY, XYY… etc.), or with the lack of one sex chromosome (X0).  
Tuner-syndrome (XO) could be observed as the most common aneuploidy during fetal life. 
However, the high rate of spontaneous abortion is decreasing its birth prevalence. Other sex 
aneuploidy are not commonly affected by spontaneous abortion like Tuner but XXX or 
Superwoman syndrome has shown a higher rate than the others, where significant difference 
between lost fetuses and newborns could not be observed. 
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Table 1 Clinical feature of aneuplody, pregnancy outcome and prognosis 
Clinical features of the aneuplody 
Trisomy Clinical Features Outcome (without iatrogenic abortion) 
21 
Cardiac defects, duodenal atresia, mild-
to-moderate mental retardation, 
thyroid problems, hearing loss, 
increased risk of leukemia, seizures 
Only 1:37 fetuses survive the intrauterine 
life and 80% of children could reach 60 yr 
of age or older 
18 
Cardiac defects, renal anomalies, severe 
mental retardation, intrauterine growth 
restriction, omphalocele, central 
nervous system defects, breathing and 
feeding difficulties, “rocker-bottom” 
feet, micrognathia, low-set ears 
Only 1 from 149 fetuses survives the 
intrauterine life and more than 90% of 
children die before or shortly after birth; 
<10% reach 1 yr of age 
13 
Cardiac defects; renal anomalies; cleft 
lip, palate, or both; holoprosencephaly; 
microcephaly; omphalocele; severe 
mental retardation; deafness; seizures 
Only 1 from 86 fetuses survives the 
intrauterine life and most children die in 
the first days or weeks of life; <10% reach 1 
yr of age. 
16 
Cardiac defects; renal anomalies; 
multiplex CNS abnormalities 
The most fetuses (99.9%) and remaining 
children die in the first days. 
X0 
Smaller height, lack or less developed 
primary and secondary genitals, 
anovulation, infertility, recurring 
miscarriage 
Only 1:1800 fetuses survive the 
intrauterine life and 90% of children could 
reach 50 yr of age or older 
XXX 
Various phenotypes are known, rate of 
infertility, gyn. cancer (cervix, breast, 
uterus) 
Only 1:5 fetuses survive the intrauterine 
life and 80% of children could reach 65 yr 
of age or older 
XXY 
Various male phenotypes are known, 
rate of infertility, higher rate of breast 
cc. 
Only 1 from 2 fetuses survives the 
intrauterine life and 80% of children could 
reach 60 yr of age or older 
Triploid 
and 
tetraploid 
Multiplex abnormalities and fetal 
hydrops could be observed. 
The most fetuses (99.9%) and remaining 
children die in the first days in intensive 
care. 
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Table 1 Summarize the prevalence of genetic syndromes in the intrauterine life and by birth. 
Table. 2. Prevalence of aneuploidy  
Affected chromosome Sp. Ab or fetal death* Newborn** 
1 0.00% 0.00% 
2 2.12% 0.00% 
3 0.71% 0.00% 
4 1.27% 0.00% 
5 0.00% 0.00% 
6–12 7.48% 0.00% 
13 1.71% 0.02% 
14 3.67% 0.00% 
15 4.24% 0.00% 
16 16.39% 0.00% 
17 0.13% 0.00% 
18 2.97% 0.02% 
19–20 0.69% 0.00% 
21 4.67% 0.13% 
22 5.65% 0.00% 
Subtotal (trisomy): 51.69% 0.17% 
Trisomy or monosomy of sex chromosomes 
XYY 0.05% 0.05% 
XXY 0.05% 0.05% 
XO 18.00% 0.01% 
XXX 0.28% 0.05% 
Subtotal (sex chr): 18.39% 0.17% 
Translocations 
Balanced 0.19% 0.19% 
Unbalanced 3.00% 0.06% 
Subtotal translocation 3.19% 0.25% 
Polyploid 
Triploid 17.00% 0.00% 
Tetraploid 6.00% 0.06% 
Other (such as mosacism) 3.73% 0.65% 
Subtotal polyploids and other 26.73% 1.29% 
Total: 100.00%*** 1.88%**** 
*Data based on 7500 spontaneous abortions with genetic analysis.  
**Data based on 85.000 births with genetic analysis.  
***Spontaneous abortion or fetal death had been associated with genetic syndromes in 
cc. 50% of all abortion cases. 
 ****Birth population had been karyotyped. 
Source: Data calculated from United States Environmental Protection Agency, Texas 
1998 
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3. Efficacy of prenatal screening and diagnostics for 
trisomies 
Hungarian Congenital Abnormality Registry is monitoring the efficiency of the screening in 
Hungary. Comparing to European results overall Hungarian detection is a bit lower than the 
average, but it could not reach the 65% since the beginning. The rate increase has been 
slowed down after 2006 and there is a need to find new techniques and finding the 
weaknesses of the screening policy.  
Most common weaknesses are the lack of the population specific normograms, lack of the 
quality control and the lack of pregnancy wide ’to do’ protocol. 
 
Figure 5 Efficacy of the prenatal screening in Hungary 2001-2009 by HCAR 
4. Basics of the ultrasound screening 
The importance of the fetal biometry reference normograms during the screening for trisomy 
is well-known (39,40)(39,40), and some preliminary studies have been highlighted the 
importance of local normal curves and charts.(41)Ton ourknowledge, theree was not any 
study to establish the Central European normograms. 
Appropriate methodology has been published fetal biometry charts and equations for various 
populations using the correct methodology are now available in the international literature. 
(39,42-45) Although there were many previous publications of the measurement and normal 
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ranges of the human fetal biometric parameters, none of all had specific data on the Central 
European Region. 
The first trimester fetal biometric characteristics have been observed, analyzed and published 
many times by the Fetal Medicine Foundation (FMF) London and its co-operators, but many 
papers highlighted the racial growth chart differences. (41,46-50) Our study was established 
based on these findings.  
The new sonography era of the screening for Down Syndrome (DS) has been started by Szabó 
and Gellén with their breakthrough publication about nuchal translucency thickness in 1990. 
(51) Following their paper many studies have been proved its clinical importance of their 
hypothesis and results. (52-56) 
From the beginning of the 20th Century, facial markers introduced to the trisomy screening. In 
the last decade, the importance of facial marker in the first(57-60) and second trimester (61-
68)was published several year ago and our good preliminary results also proved the high 
efficacy of the fetal profile ratios in the second trimester.(69) These results were suggested 
that to introduce them and to create normograms to observer these markers and ratios in the 
first trimester, too. 
The aim of the study was to establish the local fetal growth charts and normograms of fetal 
biparietal diameter, femur and humeral length, nuchal translucency, prenasal thickness, nasal 
bone length, ductus venosus PI, and PT-to-NBL and NBL-to-PT ratio from about 10weeks 
and fetal heart rate and CRL from the 37 days of gestation to the midtrimester. 
The secondary aim was to improve efficacy of screening for chromosomal abnormalities at 
the first trimester ultrasound screening.  
5. Material and Methods 
5.1. Materials: 
This prospective observational study has been designed to measure, and describe the normal 
biometric parameters. All included 4321 cases scans have been performed from January, 2008 
to February, 2014 in the MEDISONO Fetal and Maternal Health Research Centre and the 
Department of Medical Genetics, University of Szeged, Szeged, Hungary. 
This study contains for (both low- and high) mixed-risk obstetric populations, and ethnically 
over 99.8% of pregnancies were a Caucasian population of Hungary. The study protocol was 
approved by the Regional Ethics Committee of the University of Szeged and all procedures 
were in full accordance with the Helsinki Declarations. 
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5.2. Measurements  
All measurements were performed by one experienced sonographer using transabdominal 
ultrasound (GE Voluson E8 Expert, GE Healthcare Cipf, Austria). This sonographer was a 
holder of The Fetal Medicine Foundation’s (FMF) Certificate of Competence for first-
trimester scanning. All measurements were repeated for 3 times and the best one were 
selected. 
Measurements of fetal biometry such as CRL were followed the INTERGROWTH-21st 
measurement of fetal crown rump length and standardization of ultra-sonographers (2010). 
CRL was measured in the mid-sagittal section, a neutral horizontal position, using the optimal 
magnification with the correct calliper position. The intersection of the callipers were placed 
on the outer borders of the skin over the head and rump. 
NT and DVPI measurements were fully followed the FMF criteria. DVPI-to-NT and NT-to-
DVPI were established by the division NT and DVPI. 
Measurements of BPD were obtained from a transverse axial plane of the fetal head showing 
a central midline echo broken in the anterior third by the cavum septi pellucidi, if already 
present. BPD was measured from the outer border of the skull.  
The femur length (FL) was measured from the greater trochanter to the lateral condyle if it 
was exiting and shown, as if on the two ossification border of the bone.  
To measure the FHR, M-Mode was used in acquiring volume with automatic calculation.  
Facial profile (NBL and PT) 
On the basis of technical descriptions of NBL (70,71) measurements and our experience, both 
measurements could be obtained in the same image if the face of the transducer was 
positioned parallel to the nasal bone. The insonation angle should be close to 45 degrees. The 
following image settings were used: low gain, medium dynamic contrast, and maximum 
magnification so that the fetal head occupied the entire screen. Images were adjusted to ensure 
the correct midsagittal plane and sharp margins of the skin and the nasal bone. The 
diencephalon, nasal bone, lips, maxilla, and mandible were used as reference points for the 
correct measurements of NBL in the midsagittal plane (72,73). The following image settings 
were used: low gain, medium dynamic contrast, and maximum magnification so that the fetal 
head occupied the entire screen. Images were adjusted to ensure the correct midsagittal plane. 
(58,73)  Briefly, PT was measured as the shortest distance from the lower margin of the 
frontal bone to the outer surface of the overlying skin. The margins of the nasal bone are the 
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proximal and the distal ends of the white ossification line. The NBL(70,71) and PT(73) were 
measured using the same view. If it was possible NT, NBL and PT were measured on the 
same image. PT-to-NBL and NBL-to-PT were established by the division of NBL and PT. 
Additionally, between April 2008 and December 2013, 2549 women were included into 
antoher study and followed-up in the first and second trimester to improve the second 
trimester screening efficacy. First and second trimester measurements were combined in a 
normogram and compared to second trimester Down syndrome cases. 
 
5.3. Inclusion and exclusion criteria: 
All healthy singleton pregnancies have been included were not have been confirmed any 
abnormalities by the fetus and mother.  
Exclusion criteria were: IUGR, any fetal (including fetal and neonatal mortality) or maternal 
disease/ disorder, IVF or induced pregnancies, rejecting the participation of study.  
Absent nasal bone was an exclusion criteria for the facial profile ratio group. PT and NBL 
measurement were accepted if booth could be observed and measured on the same image. 
The main exclusion criteria were when the difference between the three repeated 
measurements were higher than 10% of the measured value. (Only the measurement of the 
marker was excluded in this case, not the patient case.) 
5.4. Statistical analysis and data collection 
All measurement data and volumes have been sent to astraia software (astraia GMBH, 
Münich, Germany) via DICOM. Data analysis performed by a single medical bioinformatics 
specialist with Microsoft Office 2013 (Mircosoft, Redmond, Virginia) and SYSSTAT (SyStat 
Software Inc., San Jose, CA, USA) 
Woman was referred by LMP but all data were based on the CRL measurement in this study, 
no correction have been made by other parameters. GA was calculated from CRL 
measurement at 10th week. 
Statistical analysis was performed using SigmaStat. Regression analysis was used to 
determine the percentiles (mean and 5th, 95th percentile) and regression analysis was used to 
estimate the relation between CRL and other parameters. Euploid and trisomy group were 
compared with independent sample t-test (p ≥ 0.001). 
25 
 
 
No reproducibility analysis was taken, but previous studies have been confirmed a non-
significant difference. This study not concerning about newborn or child characteristics, and 
no other maternal, neonatal or fetal biometrics were not observed. 
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6. Results 
From the 4321 women, 3356 accepted the consent form (77.67%) and participated in our 
study. Thirty seven women were excluded because of missed abortion at the first scan. One 
Edward’s syndrome case and five Down syndrome cases were diagnosed during the 
ultrasound measurements.  
Furthermore 103 cases were excluded because of maternal (26), fetal (74) or neonatal (8) 
disorders. The Edwards syndrome case had spontaneous abortion a few days after the CVS at 
11th week. Down syndrome cases were cytogenetically proved by AC during the early 
midtrimester.  
Descriptive data analysis of the results 
The mean maternal age in euploid and trisomy cases was 33.83 years (16.6–47.1 years) and 
35.83 years (26.1–41.3 years), respectively. The mean gestational age was 77. 58 days (26.0–
120 days) for euploids. The population specific  maternal age, CRL, FHR, FL, BPD, NT, 
NBL and PT descriptive statistics of euploid fetuses (mean, standard deviation,  maximum, 
75%, median, 25% and minimum values) of the euploid fetuses were summarized in Table 3. 
Table3.  Mean Std Dev 
Std. 
Error 
Max Median Min 
GA by LMP (days) 77.579 14.033 0.249 120 73 26 
NT (mm) 1.845 0.632 0.0323 6.9 1.8 0.6 
FL (mm) 8.942 2.319 0.1 16.8 8.7 3.9 
BPD (mm) 21.977 3.536 0.0786 40.9 21.5 10.08 
NBL (mm) 2.381 0.415 0.0213 4.2 2.3 1 
PT (mm) 1.412 0.369 0.019 3.2 1.4 0.1 
FHR (bpm) 162.542 15.468 0.279 215 164 68 
Ductus Venosus PI 1.099 0.165 0.00843 1.7 1.1 0.65 
The following figure series represents the results of the study and the created normograms 
with control cases. 
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Biparietal diameter (BPD) 
All biparietal diameter measurements and distribution were summarized in Figure 6.  
Normogram of Biparietal Diameter
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Where the black crosses were the measurements, black/gray line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case. 
Nuchal translucency (NT) 
All nuchal translucency measurements and distribution were summarized in Figure 7.  
Normogram of nucthal translucency thickness
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Where the black crosses were the measurements, black/gray line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case.  
28 
 
 
Embryonic or fetal heart rate (EHR /FHR) 
All fetal heart rate measurements and distribution were summarized in Figure 8.  
Normogram of Fetal Hearth Rate
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Where the black crosses were the measurements, black/gray line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red dots were the Down syndrome cases. The red rectangles were Edwards’s syndrome case. 
Femur length 
All femoral length measurements and distribution were summarized in Figure 12.  
Normogram of femoral length
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Where the black crosses were the measurements, black/gray line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case. 
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Prenasal Thickness (PT) 
All prenasal thickness measurements and distribution were summarized in Figure 10.  
Normogram of Prenasal Thickness
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Where the black crosses were the measurements, black/gray line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case. 
Nasal bone length (NBL) 
All nasal bone length measurements and distribution were summarized in Figure 11. 
Normogram of Nasal Bone Length
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Where the black crosses were the measurements, black/grey line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case.  
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Nasal bone length-to-prenasal thickness ratio (NBL:PT) 
All nasal bone length-to-prenasal thickness ratio distribution were summarized in Figure 12.  
Normogram of Nasal Bone Length-to-Prenasal Thickness Ratio
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Where the black crosses were the measurements, black/grey line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case.   
Prenasal thickness-to-nasal bone length ratio (PT:NBL) 
All prenasal thickness-to-nasal bone length ratio distribution were summarized in Figure 13.  
Normogram of Prenasal Thickness-to-Nasal Bone Length Ratio
Crown-rump length (mm)
40 60 80 100
P
re
n
a
s
a
l  T
h
ic
k
n
e
s
s
- t
o
-N
a
s
a
l B
o
n
e
 L
e
n
g
th
 R
a
ti
o
0
1
2
3
4
5
6
7
Euploid
Mean
97% Confidence Band 
3rd and 97th percentiles
Trisomy 18
Trisomy 21 (only 4 cases)
 
Where the  black crosses were the measurements, black/grey line was the median, blue lines were the 
confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. Red rectangles were 
the Down syndrome cases. The red dots were Edwards’s syndrome case.  One case with absent nasal 
bone was excluded because of the zero division. 
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Ductus venosus flow pulsatility index (DVPI) 
All ductus venosus pulsatility index distributions were summarized in Figure 14. 
The normogram of ductus venosus pulsatility index
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Where the  black crosses were the measurements, black/grey line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case. 
Nuchal translucency versus ductus venosus flow pulsatility index (NT/DVPI) 
All combined nuchal translucency and ductus venosus pulsatility index distribution were 
summarized in Figure 15.  
Combinated normogram of nucthal translucency thickness 
and ductus venosus pulatility index
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Where the black crosses were the measurements, red lines were the 1st and 99th percentiles 
limit circle. Red rectangles were the Down syndrome cases. The red dots were Edwards’s 
syndrome case. 
DVPI/NT-to-PT/NBL ratio 
All combined ductus venosus pulsatility index-to-nuchal translucency ratio versus prenasal 
thickness-to-nasal bone length ratio distribution were summarized in Figure 16. 
Distribution of the DVPI-to-NT ratio versus PT-to-NBL ratio
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Where the black crosses were the measurements, black/grey line was the median, blue lines 
were the confidence lower and upper lines, and red lines were the 3rd and 97th percentiles. 
Red rectangles were the Down syndrome cases. The red dots were Edwards’s syndrome case. 
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Statistical Performance of the markers 
Table 4 summarized the statistical performance of the marker of Down syndrome. 
Table 4.  
Statistical performance of the markers 
DR Spec LR+ LR- 
Fetal Heart Rate (FHR) 50.00 % 99.02 % 68.07 0.34 
Femur Length (FL) 40.00 % 99.07 % 43.04 0.61 
Biparietal Diameter (BPD) 40.00 % 98.79 % 33.10 0.61 
Nasal Bone Length (NBL) 66.67 % 99.17 % 80.67 0.34 
Prenasal Thickness (PT) 50.00 % 99.36 % 78.50 0.50 
NBL/PT ratio 33.33 % 98.28 % 19.42 0.68 
*PT/NBL ratio 80.00 % 98.93 % 74.56 0.20 
Nucthal Translucency (NT) 83.33 % 99.63 % 225.83 0.17 
Ductus Venosus PI 66.67 % 98.89 % 60.22 0.34 
DVPI+NT 100 % 98.51 % 67.25 <0.00 
DVPI+NT+PT/NBL ratio (3D diagram) 100 % 99.17 % 120.25 <0.00 
NT/DVPI-to-PT/NBL ratios 100 % 99.20 % 125.67 <0.00 
DVPI/NT-to-PT/NBL ratios  100 % 99.47 % 188.50 <0.00 
DR: detection rate or sentivity; Spec: Specificity (FPR=1(00%)-Spec.); LR+: 
Positive likelihood ratio; LR-: Negative likelihood ratio 
 
Significant differences were observed between euploid and trisomy group from the aspect of 
nuchal translucency, fetal heart rate, nasal bone length, prenasal thickness, ductus venosus PI, 
prenasal thickness-to-nasal bone length and ductus venous-to-nuchal translucency to prenasal 
thickness-to-nasal bone length ratios. (p > 0.001) 
IMPORTANT NOTES:  
 three times repeated measurements of NBL caused almost no measurements marked 
on 40-55mm of CRL region because difference of the measurements where higher 
than study limit (10% difference which was higher than the callipers internal space). 
 Where NBL was zero, there was a zero division in the results by PT/NBL ratio. These 
cases were excluded. 
 
Second trimester results on combined first and second trimester normograms 
Forty-one (1.6%) of 2549 were affected by trisomy 21.  Maternal age ranged from 16 to 47 
years (median 29.5) and the gestational age from 14 to 27 weeks (median 19.57 weeks). The 
nasal bone length ranged from absence (0.00 mm) to 12 mm and volume capture duration 
ranged from 1 to 49 minutes (median 7 minutes).  
34 
 
 
 
Where the black crosses were the euploid measurements, black/grey line was the median, blue 
lines were the confidence lower and upper lines, and red lines were the 3rd and 97th 
percentiles in Figure 17  
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Where the  black crosses were the trisomy 21 measurements, black/grey line was the median, 
blue lines were the confidence lower and upper lines, and red lines were the 3rd and 97th 
percentiles in Figure 18. 
Down syndrome cases were plotted on normogram (Figure 2). Cut-off value was setup to the 
5th percentiles line.  Forty-one cases of trisomy 21 were identified (cytogenetically) and all of 
them were detected between 14th and 28thweeks. In 33 cases the measured NBL values were 
lower than the 5th percentile and 8 cases of trisomy 21 fetuses were higher than 5th percentile, 
respectively. These results showed 80.49% sensitivity with 98.17% specificity. (See in Table 
3.). Positive and negative likelihood ratio for trisomy 21 fetuses were 43.98 and 0.2, 
respectively.There was significant difference between the nasal bone length of euploid and 
trisomy 21 fetuses  (P =< 0.001). 
7. Discussion 
7.1. The explanation of the results 
This study represented the high sensitivity ultrasound screening methods and reference charts 
of the fetal biometric parameters of the Caucasian population.  
NT was the first and the most sensitive screening marker of Down syndrome. This study 
proved its strength in first trimester screening.  
DVPI was found one of the most sensitive marker of trisomies during the first trimester. It has 
high sensitivity and a medium-high specificity on trisomies. This finding was also confirmed 
by our study. 
The most sensitive marker was the combined DVPI and NT plot, but the best result was 
reached when NT and DVPI were combined with the facial markers.  
Our preliminary results were proved the efficacy of PT, NBL and their ratios in the second 
trimester. Slightly, these markers were fitted to the first trimester scan. They could be 
measured easily on the same image with NT. The common measurement, possibility could 
decrease the necessary time of observation and extremely increase efficacy of screening.  In 
contrast with previous result PT-to-NBL is overwhelming in the first trimester. 
The FL, BPD and HL should act as an important screening marker of the early IUGR and not 
for the trisomies. These markers may help to identify the bi- and unilateral cranial and limb 
anomalies during the first trimester. 
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The clinical aspects of these findings were the introduction of the facial profile ratio to the 
first trimester screening, using DVPI-to-NT and PT-to-NBL ratios in the first trimester as new 
markers of trisomies.   
The ductus venosus-to-nuchal translucency to prenasal thickness-to-nasal bone length ratio 
reached an impressive 100% detection rate of 0.6% false positive rate. The risk of 
chromosomal defects is very high and the first line of management of such pregnancies 
should be the offer of NIPT or chorionic villus sampling (CVS) for fetal karyotyping. 
The latest screening strategy for first and second trimester was introduced by Nicolaides et al. 
in a congress. (Advances in Fetal Medicine Dec 2013 London). Their opinion was to focus on 
the neck on first and focus on the face (facial profile) in the second trimester. These was a 
summary of the long development and research of the screening for trisomy, booth direction 
were introduced and published from several groups in last two and the half decades. 
(51,53,60,65,69,70,74-83)  
CRL, BPD, FHR and FL were measured from the beginning of the obstetric ultrasound era. 
These markers were easily measured with the low-resolution devices, but provided much 
useful information about fetal development to the examiner. Our study had been set the 
normograms of these markers and tried to use them in the screening for trisomy. Excluding 
FHR, these markers have efficacy in the developmental and well-being scans, and they should 
not be used for trisomy screening. FHR proved a really high sensitivity and a fair specificity 
to detect fetal defects in the early pregnancy. Our previous observation also proved its 
importance during the early first trimester scans to find the pregnancy outcome or the early 
and late fetal loss from the 6 weeks.(84) 
NT were the real first marker of autosomal trisomies (51) but several study proved its 
usefulness in different conditions and diseases (See Appendix Table 1).(75) Current paper 
used NT after the first trimester and proved a really good efficacy on trisomy.  
Nasal bone length was proved high screening efficacy during the pregnancy. However, in the 
first trimester its repeatability is very low and there is no linear increase till 60mm of CRL, 
but the production lines were padded to the border of the plot and it was useful to screen out 
cases in the early pregnancy.  
Prenasal thickness (PT) was published a several years later by Maymon et. al. PT(65)  was 
improved the second trimester screening efficacy for trimsomies. Current study as a 
preliminary studies(85) before used  PT as a first trimester marker –successfully. Szabó et 
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al.(69) published facial profile based ratios and its inverse counterpart  and proposed that they 
could be utilized as well in the first trimester. This study confirms the usefulness of these 
markers in the first trimester.  However, during the second trimester NBL-to-PT was better 
than the PT-to-NBL, although PT-to-NBL was better in the first trimester. The problem with 
this ratio is the zero division so if there is no nasal bone, it is unable to use for risk estimation. 
7.2. The limitations of the study  
The limitations were the local population and strict inclusion policy of the healthy euploid 
cases and the number of the overall cases and patient number of trisomy group. 
Another limitation of the study is the nasal bone development; margins of the nasal should be 
identified. 
7.3. Combined normograms 
 
Table 5. Fetal nasal bone length normogram and trisomy 21 : review of the literature 
Authors  Population Method Case Tr21 DR FPR LR+ 
Bromley et al. 2002(3) Mixed 2D 239 16 69 5 11 
Cicero et al. 2003 (4) Mixed 2D 1016 34 60 1 
50.50x  
132x* 
Bunduki et al. 2003 (5) Mixed 2D 1631 22 59.1 5.1 11.6x 
Chen et al. 2004 (9) Chinese 2D 198 NI N/A N/A N/A 
Benoit et al. 2005 (6) Mixed 3D 38 20 75 8 N/A 
Sutthibenjakul et al. 2009 (12) Thai & 
mixed 
2D 295 18 77.7 0.7 N/A 
Geipel et al. 2010 (17) mixed 3D 870 37 65 5.8 14x 
Szabó et al. 2014 (16) Caucasian 2D 1330 33 75.8 1.88 41,32 
This study in 2014 Caucasian 2D 2590  41 80.5 1.83 43.98x 
Population : population of the study; Method : 2D or 3D ultrasound were performed.; cases: 
number of euploid cases; Tr21 : number of trisomy 21 cases; DR : detection rate; FPR : false 
positive rate; LR+ : likelihood ratio;  
*by Caucasians 
*N/A not applicable or not available; NI : not included 
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Our data demonstrate that hypoplastic nasal bone between 14 and 28th gestational weeks was 
found in 1.83% of euploid and 80.49% of trisomy 21 fetuses, respectively. These findings are 
showed a better screening performance than to previous studies with 2D ultrasound. (8, 16) 
The nasal bone length was used as an isolated marker in our study. However, other studies 
used nasal bone length in combination bi-parietal diameter (BPD), femur length (FL) and 
moreover they used multiple of medians (MoMs) values instead of simple measurement value 
in millimetres. Our analysis showed that using MoMs in a statistical evaluation is misleading. 
Since the millimetre measurements day-by-day are more reliable and much easier to use in 
practice than a more complex summarized and corrigated values.   
Fifty-one (1.83%)  out of 2549 euploid fetuses fell under 5th percentile While 8 (19.51%) 
trisomy 21 fetuses had nasal bone length higher than 5th percentile. The nasal bone was 
present but hypoplastic in 33 (80.49%) out of 41 trisomy 21 cases.  
7.4. Practical and clinical aspects 
To use these normograms some basic recommendation is still necessary. 
Repeated measurements are strongly recommended to exclude the medical, technical, 
measurement and visual errors. If the visualization is not enough good, then the examination, 
it should be repeated in another time/day/. 
Ultrasound scans and biochemical screening are still required during the trimesters. The 
screening for trisomy shoud be more ultrasonographic oriented and extended with NBL, PT. 
These results lead up to 90% sensitivity, if biochemical screening is preformed than it could 
reach 95% of sensitivity.  Higher-risk patients should be sent to the genetics department for a 
counselling of the diagnostics ways of the invasive procedures which will be required for the 
diagnosis and performed only after genetic counselling. This study could improved the 
efficacy of screening. 
If the risk was low, but fetal growth is lower the normograms than IUGR is possible, but the 
measurements and dating must be rechecked to exclude the possible errors. In several cases, 
using the LMP to set GA leads to the wrong dating of pregnancy, so use CRL results to GA or 
changing markers when there is no automatized data transfer. In patients with a family history 
or maternal (and/or parental) anxiety of genetic syndromes that can be diagnosed by DNA 
analysis, the NIPT by some syndromes or the CVS sample can also be tested for these 
syndromes. 
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Place of the noninvasive prenatal tests in screening for trisomy 
First of all, noninvasive prenatal tests (NIPT) are more widely offered in the wealthy and 
developed countries and its efficacy in screening for trisomies.  
On the other hand, NIPT overall screening (not diagnostic) performance is 99,5% of 1% of 
FPR which is impressive for a bit less than 1000EUR. However, ultrasound scans are still 
necessary to observe the fetal biometry for screening of other fetal structural and 
developmental disorder for a less than 70EUR. So it is more than dangerous, if the extended 
(anomaly) scans have been spent for a NIPT only.  
It must not be forget that NIPT always remains a screening test, when invasive procedure 
offers  
Figure 17 Show the developed screening and consultation methodology of trisomy. 
 
This methodology provides the optimal prenatal care also in low-income countries where the 
full spectrum of biochemical screening and NIPT is not widely available for average citizens. 
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Conclusions 
Local normograms and the most sensitive ultrasound screening model for trisomy 21, and 18 
were introduced. Using these ratios could be comparable with NIPT. These measurements and 
methods should be incorporated into first trimester screening for trisomy.  Further 
investigation will be necessary to observe these findings on different population and also in 
the second and third trimester.  
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8. Clinical conclusions of the study 
 The increasing prevalence of DS can be primarily attributed to the increasing ratio of 
advanced age of mothers and changes of the entertainment especially the diet 
 Prenatal screening could show a significant improvement year by year if our 
normogram and protocol could be introduced. 
 The prevalence of Down syndrome and the efficiency of prenatal screening was 
slightly lower than the values observed in other European countries, but new 
references and protocol could lead to a better result such as it happened in Denmark. 
 The increasing geographical inequalities in screening effectiveness demonstrated the 
existence of non-exploited opportunities in certain (non-properly managed) areas of 
Hungary by HCAR but 2D ultrasound is commonly used in the obstetrics and these 
markers could be easily measured in 5-15 minutes. 
 Some clinical and practical training should be offered to involve the physicians to the 
screening. 
 The combination of different ratio might be working in the second trimester screening, 
too. 
 It is possible to improve screening efficacy if first and second trimester measurement 
of NBL is combined on a normogram. 
 Combining different ratios could be beneficially by other markers, too. 
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9. New findings and newly developed methods in the 
thesis  
 We first described the definition of “prevention in fetal medicine” 
 We first described the national normograms of the fetal biometry parameters of the 
Hungarian population. 
 We first described a new practical-based, easy-to-use and cost-effective two-
dimensional measurement techniques of the NBL and PT in the first trimester. 
 We first described a high risk pregnancy management protocol for low income 
countries 
 We first described that the NIPT how to be placed into the screening system in 
Hungary. 
 We first described that the combined the first and second trimester normogram to 
enhance the efficacy of the second trimester screening of nasal bone length. 
 We first described in the international literature who introduced NBL and PT with 
their ratios in the first trimester. 
 We first described that the combination of different ratios could increase the screening 
efficiency in the first trimester. 
 We first described that highest sensitivity and specificity could be reached for the 
bedside in the first trimester without any biochemical or DNA test. 
 We first described that development of a statistical method to a practical method of the 
ultrasound screening, which has comparable screening performance to NIPT but much 
cheaper and could be widely used also in the low income countries. 
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10. New observations during my fellowship 
1) In the major trisomy markers of euploid and trisomy fetuses a significant difference was 
observed. 
2) We elaborated the method how the fetal nasal bone length (NBL) and prenasal thickness 
(PT) can be obtained and measured in a single volume acquisition (image) during the 
first trimester anatomy scan.  
3) Validated normograms have been created for the Hungarian population for the first and 
second trimester. 
4) We first demonstrated the combination of nasal bone length (NBL) and prenasal 
thickness (PT) as a ratio could be used in the first trimester as a screening marker of 
aneuploidies. 
5) These data have been supported previous observations which highlighted the importance 
of nuchal translucency and ductus venosus flow pulsatility index as the most effective 
screening co-maker of autosomal trisomy. 
6) We first demonstrated the combination of nuchal translucency and ductus venosus flow 
pulsatility index as a ratio versus the combination of nasal bone length (NBL) and 
prenasal thickness (PT) as a ratio, could be used in the first trimester as a more sensitive 
ultrasonography screening marker of aneuploidies. 
7) We first described in the international literature that the combination of first and second 
trimester NBL measurement on a mixed normogram could increase the efficacy of 
screening in the second trimester. 
8) We first described in the international literature that the PT: NBL and NBL: PT ratio in 
the first trimester. 
9) We first published in the international literature that the ultrasound measurements of 
these new markers can successfully be incorporated into the first and second trimester 
fetal anatomy scan. 
10) We first described in the Hungarian literature that how to create and validate obstetrical 
normograms.  
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Appendix 
 
Appendix table 1. Increased NT thickness 
associated fetal disorders 
Venous congestion localized to the head and neck 
Cardiac defects / dysfunction 
Fetal anemia 
Fetal hypoproteinemia /nephrosis 
Fetal infection (ei. Parvo B13) 
Altered composition of extracellular matrix 
Failure of lymphatic drainage 
 
 
Appendix table 2. First trimester major and minor markers of Down Syndrome 
Nuchal thickening  
 Hyperechoic bowel 
Absent nasal bone  
Short humerus  
 Short femur  
 EIF  
 Pyelectasis 
 
Mouth/cleft disorder 
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